Pregnancy Outcomes After Maternal or Paternal Exposure to Tofacitinib Across Clinical Programs.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 41002213.
- Also identified by DOI 10.14309/ajg.0000000000003774 and PMC identifier 12854357.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This analysis reports updated pregnancy outcomes after tofacitinib exposure in patients with immune-mediated diseases. Pregnancy/partner pregnancy cases from interventional studies were identified in Pfizer safety database through March 2023. Of 184 pregnancies reported, 85 were maternal exposure events: 46 healthy newborns, 12 medical terminations, 1 fetal death, 1 congenital malformation, 14 spontaneous abortions, and 11 pending/lost to follow-up. There were 99 paternal exposure events: 67 healthy newborns, 1 fetal death, 9 spontaneous abortions, and 22 pending/lost to follow-up. Outcomes of maternal/paternal tofacitinib exposure were similar to those expected in the general population; tofacitinib should not be used during pregnancy unless clearly necessary.
Medical subject headings
- Pregnancy Outcome
- Pyrimidines
- Piperidines
- Paternal Exposure
- Protein Kinase Inhibitors
- Maternal Exposure
- Pregnancy Complications